Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Jul 5;132(1):59-66.
doi: 10.1182/blood-2018-04-842880. Epub 2018 May 21.

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

Affiliations
Clinical Trial

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma

Leo Rasche et al. Blood. .

Abstract

Spatial intratumor heterogeneity is frequently seen in multiple myeloma (MM) and poses a significant challenge for risk classifiers, which rely on tumor samples from the iliac crest. Because biopsy-based assessment of multiple skeletal sites is difficult, alternative strategies for risk stratification are required. Recently, the size of focal lesions (FLs) was shown to be a surrogate marker for spatial heterogeneity, suggesting that data from medical imaging could be used to improve risk stratification approaches. Here, we investigated the prognostic value of FL size in 404 transplant-eligible, newly diagnosed MM patients. Using diffusion-weighted magnetic resonance imaging with background suppression, we identified the presence of multiple large FLs as a strong prognostic factor. Patients with at least 3 large FLs with a product of the perpendicular diameters >5 cm2 were associated with poor progression-free survival (PFS) and overall survival (OS; median, 2.3 and 3.6 years, respectively). This pattern, seen in 13.8% of patients, was independent of the Revised International Staging System (RISS), gene expression profiling (GEP)-based risk score, gain(1q), or extramedullary disease (hazard ratio, 2.7 and 2.2 for PFS and OS in multivariate analysis, respectively). The number of FLs lost its negative impact on outcome after adjusting for FL size. In conclusion, the presence of at least 3 large FL is a feature of high risk, which can be used to refine the diagnosis of this type of disease behavior and as an entry criterion for risk-stratified trials.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: B.B. is a coinventor on patents and patent applications related to use of gene expression profiling in cancer medicine that have been licensed to Quest Diagnostics. The remaining authors declare no competing financial interests.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
The impact of focal lesion size on outcome. (A) The FL-HiR pattern as seen in whole-body diffusion-weighted MRI scan with background suppression. It consists of ≥3 large FLs, each with a PPD ≥5 cm2. (B) Outcome of 404 NDMM patients enrolled into Total Therapy trials stratified by this pattern. Log-rank test was used to perform the group comparison.
Figure 2.
Figure 2.
Association test and multivariate analysis including the FL-HiR pattern. (A) Association between the FL-HiR pattern and disease features. Statistical significance was determined by Fisher’s exact test. (B) Forrest plot illustrating the results of a Cox regression model including the depicted variables. Hazard ratios and 95% confidence intervals are indicated by squares and crossing horizontal lines, respectively. *P < .05; **P < .01; ***P < .001. AIC, Akaike information criterion.
Figure 3.
Figure 3.
Combination of FL-HiR with established risk stratifiers. Progression-free survival for newly diagnosed MM patients stratified by the combination of the FL-HiR pattern with R-ISS (left) and GEP70 (right), respectively. The log-rank test was used to calculate P values.

References

    1. Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543-556. - PubMed
    1. Palumbo A, Avet-Loiseau H, Oliva S, et al. . Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869. - PMC - PubMed
    1. Shaughnessy JD Jr, Zhan F, Burington BE, et al. . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284. - PubMed
    1. Hillengass J, Fechtner K, Weber MA, et al. . Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28(9):1606-1610. - PubMed
    1. Usmani SZ, Mitchell A, Waheed S, et al. . Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood. 2013;121(10):1819-1823. - PMC - PubMed

Publication types